Spencer Pharmaceutical Inc(SPPH)
USD --+0.00%
Reward44Moderate
Risk44Moderate
📊50%Data
SPPH
+0.0 · +0.00%
USD · OTCCE
Spencer Pharmaceutical Inc | Healthcare
Capital Destroyer
Market Cap:1.34M
ℹ️
Reward Rating
44
Moderate
Bottom 25% (model universe)
50% data coverage
ℹ️
Risk Rating
44
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on SPPH to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Spencer Pharmaceutical Inc?

develops drug platform technologies for the treatment of neurological deceases.

SPPH · Verdict

Moderate reward · moderate risk

SPPH stands out on cash flow and balance sheet, but watch the volatility signal.

Based on 75% data coverage

SPPH · Verdict

What’s working & what to watch

Strengths 2

  • Cash flow95/100

    Top decile vs peers

  • Balance sheet68/100

    Current ratio 0.28

Watchouts 2

  • Volatility5/100

    Weak vs peers

  • Profitability10/100

    0% return on equity

Model-based scoring. For information only — not financial advice.

What is Spencer Pharmaceutical Inc?

develops drug platform technologies for the treatment of neurological deceases. The company specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential applications. The company is listed on the OTCCE in USA, operating in the Healthcare sector, with a market capitalisation of 1.34M.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (44)

The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap1.34M
P/E RatioN/A
Dividend YieldN/A
52 Week High0.0001
52 Week Low0.0001
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares OutstandingN/A
No. of EmployeesN/A
IndustryBiotechnology
ExchangeOTCCE
Beta55.835
CurrencyUSD
WebsiteN/A